Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study

References

• WHO. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2013. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (accessed 2013 December 30).
   Google Scholar
• Chen YS, Xu SX, Ding YB, Huang XE, Deng B, Gao XF, et al. Colorectal cancer screening in high-risk populations: a survey of cognition among medical professionals in Jiangsu, China. Asian Pac J Cancer Prev. 2013;14(11):6487–91.
   Google Scholar
• Kerr D. Clinical development of gene therapy for colorectal cancer. Nat Rev Cancer. 2003;3(8):615–22.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010;375(9719):1030–47.
   PubMed Web of Science ®Google Scholar
• Tebbutt NC, Cattell E, Midgley R, Cunningham D, Kerr D. Systemic treatment of colorectal cancer. Eur J Cancer. 2002;38(7):1000–15.
   PubMed Web of Science ®Google Scholar
• Chiu J, Tang V, Leung R, Wong H, Chu KW, Poon J, et al. Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis. Asian Pac J Cancer Prev. 2013;14(11):6585–90.
   Google Scholar
• Gallagher DJ, Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology. 2010;78(3–4):237–48.
   PubMed Web of Science ®Google Scholar
• Liao WJ, Shen P, Wu W, Shi M, Luo RC. [Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer]. Nan Fang Yi Ke Da Xue Xue Bao. 2010;30(4):813–4.
   PubMedGoogle Scholar
• Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer. 2007;7:91.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23(15):3502–8.
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23(16):3706–12.
   PubMed Web of Science ®Google Scholar
• Popov I, Milicevic M, Radosevic-Jelic L. The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy. Acta Chirurgica Iugoslavica. 2008;55(4):11–16.
   PubMedGoogle Scholar
• Xu HX, Huang XE, Qian ZY, Xu X, Li Y, Li CG. Clinical observation of Endostar(R) combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev. 2011;12(11):3087–90.
   PubMedGoogle Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–14.
   PubMed Web of Science ®Google Scholar
• Kohne CH, vanCutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol. 2005;23(22):4856–65.
   PubMed Web of Science ®Google Scholar
• Fuchs C, Marshall J, Mitchell E. A randomized, multi-center phase III trial of irinotecan in combination with three different methods of administration of fluoropyrimidine with celecoxib versus placebo as first-line treatment for patients with metastatic colorectal cancer. J Clin Oncol. 2007;25(18 Suppl):170s. [Abstract #4027].
   Google Scholar
• Kopetz S, Glover KY, Eng C. Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer. J Clin Oncol. 2007;25(18 Suppl):185s.
   Google Scholar
• Sobrero AF, Young S, Balcewicz S. Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI. J Clin Oncol. 2007;25(18 Suppl):180s.
   PubMedGoogle Scholar
• O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277–85.
   PubMed Web of Science ®Google Scholar
• Dhanabal M, Volk R, Ramchandran R, Simons M, Sukhatme VP. Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun. 1999;258(2):345–52.
   PubMed Web of Science ®Google Scholar
• Hanai J, Dhanabal M, Karumanchi SA, Albanese C, Waterman M, Chan B, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem. 2002;277(19):16464–9.
   PubMed Web of Science ®Google Scholar
• Dixelius J, Larsson H, Sasaki T, Holmqvist K, Lu L, Engstrom A, et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood. 2000;95(11):3403–11.
   PubMed Web of Science ®Google Scholar
• Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A. 2003;100(8):4766–71.
   PubMed Web of Science ®Google Scholar
• Wang J, Sun Y, Liu Y, Yu Q, Zhang Y, Li K, et al. [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi. 2005;8(4):283–90.
   PubMedGoogle Scholar